| News

Idorsia receives payment of 45 million US dollars

12.05.2020

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy.

Idorsia headquarter in Allschwil (img: Idorsia)

Idorsia has developed a T-type calcium channel blocker in the form of ACT-709478 that should facilitate treatment of a rare form of epilepsy in children. According to a press release, Idorsia has agreed a licensing agreement with Neurocrine Biosciences. As the US company has now decided to take up its option to license the global development and marketing rights to ACT-709478, Idorsia is set to receive fixed payments as part of the agreement.

In this context, the company based in Allschwil receives an upfront payment of 45 million US dollars. Moreover, Idorsia will be entitled to claim milestone payments up to a potential total of 365 million US dollars in addition to tiered royalties dependent on net sales figures. Neurocrine Biosciences is already planning to launch a Phase II study in the second half of 2020.

“If the efficacy of our selective T-type calcium channel blocker seen in preclinical models is confirmed in children with rare pediatric epilepsy, it could transform the life of children with this disease”, comments Martine Clozel, Chief Scientific Officer of Idorsia, in the press release. Furthermore, this is a case where collaborating with a partner allows greater progress to be made in further development processes.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation

docdok.health involved in coronavirus research project

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

Read More
Basel Area Business & Innovation, Innovation

Celonic agrees cooperation to combat coronavirus

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

Read More
Basel Area Business & Innovation, Innovation, Invest

Idorsia receives payment of 45 million US dollars

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..

Read More
Basel Area Business & Innovation, Innovation

Humard robot disinfects using UV light

Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.

Read More
Basel Area Business & Innovation, Innovation, Invest

Roche authorized to distribute coronavirus antibody tests

Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.

Read More
Basel Area Business & Innovation, Invest

Basel is the most popular Swiss location for headquarters

Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.